FRESENIUS KABI USA LLC for FRESENIUS KABI USA LLC
What was lobbied
10 issue areas, each in the filer's own words, with who lobbied on it and where.
Disaster Planning/Emergencies DIS
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Manufacturing MAN
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Taxation/Internal Revenue Code TAX
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Accounting ACC
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Labor Issues/Antitrust/Workplace LBR
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Pharmacy PHA
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Budget/Appropriations BUD
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Medical/Disease Research/Clinical Labs MED
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Science/Technology SCI
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Health Issues HCR
Issues impacting the pharmaceutical industry, including coverage, coding, and payment policy for both public and private payers, regulatory, tax, trade, manufacturing, and intellectual property.
| Lobbyist | Covered position, as disclosed |
|---|---|
| TIMOTHY CASEY New | Office of Senator Tom Carper (D-DE) Office of Congressman John Tierney (D-MA) |
| SARAH CHRISTINE D'ORSIE New | Office of Congressman Tom Davis (R-VA), Professional Staff, House Government Reform and Oversight Committee |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| FRESENIUS KABI SWISSBIOSIM GMBH | Switzerland | Switzerland | 100.0% | $165,532 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.